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Abstract
The food enzyme considered in this opinion is a glucan 1,4-a-maltohydrolase (maltogenic a-amylase; EC
3.2.1.133) produced with the genetically modified Bacillus subtilis strain MAM by the company DSM Food
Specialties B. V. The food enzyme contains neither the production microorganism nor recombinant DNA;
therefore, no environmental risk assessment is required. However, the Panel emphasises that this
conclusion only covers the food enzyme recovered via filter press. The glucan 1,4-a-maltohydrolase is
intended for use in baking processes. Based on the maximum use levels recommended and individual
consumption data from the EFSA Comprehensive European Food Consumption Database, dietary
exposure to the food enzyme-total organic solids (TOS) was estimated to be up to 0.175 mg TOS/kg
body weight (bw) per day in European populations. The systemic toxicity was assessed by means of a
repeated dose 90-day oral toxicity study in rodents. A no observed adverse effect level (NOAEL) was
derived (986 mg TOS/kg bw per day for both males and females), which, compared with the dietary
exposure, results in a sufficiently high margin of exposure. The allergenicity was evaluated by comparing
the amino acid sequence to those of known allergens; one match was found. However, the
Panel considered that there are no indications for food allergic reactions to this glucan 1,4-a-
maltohydrolase by dietary exposure. No safety concerns were identified in relation to the genetic
modifications, the manufacturing process, the compositional data provided, as well as the exposure,
allergenicity and systemic toxicity assessments. However, owing to the incompleteness of the
genotoxicity data, the Panel is not able to conclude on the safety of the food enzyme.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
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1. Introduction
Article 3 of the Regulation (EC) No 1332/20081 provides definitions for ‘food enzyme’ and ‘food
enzyme preparation’.
‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products
thereof including a product obtained by a fermentation process using microorganisms: (i) containing
one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a
technological purpose at any stage of the manufacturing, processing, preparation, treatment,
packaging, transport or storage of foods.
‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which
substances such as food additives and/or other food ingredients are incorporated to facilitate their
storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or
were regulated as processing aids under the legislation of the Member States. On 20 January 2009,
Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes
that are added to food to perform a technological function in the manufacture, processing,
preparation, treatment, packaging, transport or storage of such food, including enzymes used as
processing aids. Regulation (EC) No 1331/2008 established the European Union (EU) procedures for
the safety assessment and the authorisation procedure of food additives, food enzymes and food
flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
• it does not pose a safety concern to the health of the consumer at the level of use proposed;
• there is a reasonable technological need;
• its use does not mislead the consumer.
All food enzymes currently on the EU market and intended to remain on that market, as well as all
new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority
(EFSA) and an approval via a Union list.
The ‘Guidance on submission of a dossier on a food enzyme for evaluation’ (EFSA, 2009a) lays
down the administrative, technical and toxicological data required.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background as provided by the European Commission
Only food enzymes included in the Union list may be placed on the market as such and used in
foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of
Regulation (EC) No 1332/2008 on food enzymes.
Two applications have been introduced by the companies Novozymes A/S and DSM Food Specialties
B. V. for the authorisation of the food enzymes Xylanase from a genetically modified strain of
Aspergillus oryzae (strain NZYM-FA) and Glucan 1,4-a-maltohydrolase from a genetically modified
strain of Bacillus subtilis (strain MAM), respectively.
Following the requirements of Article 12.1 of Commission Regulation (EC) No 234/20112
implementing Regulation (EC) No 1331/20083, the Commission has verified that the two applications
fall within the scope of the food enzyme Regulation and contain all the elements required under
Chapter II of that Regulation.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority to carry out the safety
assessment on the food enzymes Xylanase from a genetically modified strain of Aspergillus oryzae
(strain NZYM-FA) and Glucan 1,4-a-maltohydrolase from a genetically modified strain of Bacillus subtilis
(strain MAM) in accordance with the article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.
1 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and
Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive
2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7–15.
2 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European
Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food
flavourings. OJ L 64, 11.3.2011, p. 15–24.
3 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1–6.
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1.2. Interpretation of the Terms of Reference
The present scientific opinion addresses the European Commission’s request to carry out the safety
assessment of the food enzyme glucan 1,4-a-maltohydrolase produced with Bacillus subtilis (strain
MAM) submitted by DSM Food Specialties B. V.
1.3. Information on existing authorisations and evaluations
The applicant reports that the Russian food authorities have evaluated and authorised the use of a
glucan 1,4-a-maltohydrolase from a genetically modified B. subtilis strain MAM 14 for a number of food
manufacturing processes.
2. Data and methodologies
2.1. Data
The applicant submitted a dossier supporting the application for authorisation of the food enzyme
glucan 1,4-a-maltohydrolase produced with a genetically modified B. subtilis strain MAM. The food
enzyme is intended to be used in baking processes.
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientific aspects of risk assessment (EFSA, 2009b) and following the relevant
Guidances from the EFSA Scientific Committee.
The current ‘Guidance on the submission of a dossier for safety evaluation of a food enzyme’
(EFSA, 2009a) has been followed by the CEF Panel for the evaluation of the application with the
exception of the exposure assessment, which was carried out in accordance to the methodology




3.1.1. Identity of the food enzyme
IUBMB nomenclature: Glucan 1,4-a-maltohydrolase
Systematic name: 4-a-D-glucan a-maltohydrolase
Synonyms: Maltogenic a-amylase
IUBMB No: EC 3.2.1.133
CAS No: 160611-47-2.
3.1.2. Chemical parameters
The glucan 1,4-a-maltohydrolase (maltogenic a-amylase) produced with the genetically modified
B. subtilis strain MAM consists of a single polypeptide of 719 amino acids, including a signal peptide of
33 amino acids, which is cleaved off during secretion of the enzyme protein. The molecular mass of
the enzyme protein of 66 kDa was estimated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) analysis, which was also used to investigate the protein homogeneity of
the food enzyme. The gels presented showed one main protein band and some minor protein bands of
lower molecular mass. No enzymatic side activities have been reported by the applicant.
Data on the chemical parameters and the protein homogeneity of the food enzyme were provided
for four food enzyme batches, three batches to be used for commercialisation and one batch used for
the toxicological tests (Table 1). The average total organic solids (TOS) of the three food enzyme
batches for commercialisation was 6.3%; the values ranged from 4.7% to 8.4%.
The average enzyme activity/TOS ratio of the three food enzyme batches for commercialisation was
205 New Maltogenic Amylase Units (NMAU)/mg TOS; the values ranged from 176 to 249 NMAU/mg
TOS (Table 1).
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The lead content on the three commercial batches and the batch used for toxicological studies was
below 2 mg/kg which complies with the specification for lead (≤ 5 mg/kg) as laid down in the general
specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).
No antimicrobial activity was detected in any of these batches (FAO/WHO 2006).
The food enzyme complies with the microbiological criteria as laid down in the general
specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which
stipulate that Escherichia coli and Salmonella species are absent in 25 g of sample and total coliforms
should not exceed 30 colony forming units (CFU) per gram.
The applicant has provided information on the identity of the antifoam agent used and the method
used for analysis. Taking into account the nature and properties of the antifoam agent, the
manufacturing process and the quality assurance system implemented by the applicant, the
Panel considers its use as of no safety concern.
The compositional data provided for the food enzyme batches are considered sufficient.
3.1.3. Properties of the food enzyme
The food enzyme catalyses the hydrolysis of (1?4)-a-D-glucosidic linkages in polysaccharides like
starch, removing successively maltose units from the non-reducing ends of the chains.
The enzymatic activity is determined on the basis of an in-house testing using a maltotriose
standard and expressed in NMAU/g (reaction conditions: pH = 5.0, T = 37°C, incubation time 5 min).
The enzymatic hydrolysis of maltotriose results in release of glucose, which is quantitatively measured
using the Ecoline S + Glucose Hexokinase kit. The released glucose is converted into gluconate-6-P in
two steps, in which NADH is formed. The resulting increase in absorbance at 340 nm is a measure for
the amount of released glucose and, accordingly, a measure of the maltogenic a-amylase activity. One
NMAU is defined as the amount of enzyme that produces 1 lmol glucose per minute using maltotriose
substrate under the defined assay conditions.
The food enzyme has been characterised regarding its temperature and pH profiles. The glucan
1,4-a-maltohydrolase is active up to 90°C (with an optimum around 65°C) and within a pH range of
3.5–6.5 (with an optimum around pH 5). The enzyme shows 75% residual activity at approximately
80°C after 30 min, and no activity at temperatures above 90°C.
3.1.4. Information on the source material
3.1.4.1. Information on the genetically modified microorganism
The technical dossier contains detailed information on the recipient microorganism, the donor
organism and the genetic modification process.
According to the CEF Guidance, the certificate of deposit of the production strain in a public
validated culture collection should be provided. The applicant deposited the glucan 1,4-a-
maltohydrolase production strain B. subtilis MAM only in the under code
. The Panel noted that this would not allow a verification of the strain independently of the
company.
Table 1: Compositional data of the food enzyme
Parameter Unit
Batch
1 2 3 4(a)
Glucan 1,4-a-maltohydrolase activity NMAU/g batch(b) 14,800 14,200 8,950 10,455
Protein % 3.8 3.4 2.6 3.8
Ash % 2.0 1.1 1.2 1.0
Water % 89.6 93.2 94.1 91.9
Total organic solids (TOS)(c) % 8.4 5.7 4.7 7.1
Activity/mg TOS NMAU/mg TOS 176 249 190 147
(a): Batch used for the toxicological studies.
(b): NMAU: New Maltogenic Amylase Units (see Section 3.1.3).
(c): TOS calculated as 100% – % water – % ash – % diluents.
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3.1.4.2. Characteristics of the parental and recipient microorganisms
3.1.4.3. Characteristics of the donor microorganisms
3.1.4.4. Description of the genetic modification process
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3.1.4.5. Safety aspects of the genetic modification
3.1.5. Manufacturing process
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/20044
and in accordance with current Good Manufacturing Practice (GMP). The manufacturing process is
certified according to Food Safety Systems Certification 22000 (FSSC 22000). A data set related to the
manufacturing process including a list of raw materials used and a production flow process from
fermentation and downstream processes was provided.
The food enzyme is produced by a pure culture of B. subtilis MAM in a contained, submerged, fed-
batch fermentation system with conventional process controls in place. The identity and purity of the
culture are checked at each transfer step from frozen vials to the end of fermentation.
The downstream processing includes a pretreatment, recovery, purification and concentration. The
pretreatment comprises killing of the cells
. Upon request by the Panel, the applicant provided data on the use of
these agents in the fermentation broth. However, their concentrations in the food enzyme were not
given. Therefore, a conclusion cannot be reached on compliance of the food enzyme with the
requirements of Regulation (EC) No 1333/20085
According to the applicant, only the filter press procedure is currently applied in regular production.
However, the applicant emphasises that the use of microfiltration is maintained as an option for further
production. Data for this recovery route were not provided.
4 Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives.
OJ L 226, 25.6.2004, p. 3–21.
5 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16–33.
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The absence of DNA only relates to the recovery route involving the application of filter press. The
respective data referring to the use of microfiltration or centrifugation have not been provided by the
applicant.
The production strain could not be detected in samples from three fermentations taken after the
chemical killing process. No recombinant DNA was detected by PCR in three batches from the filter
press recovery route.
The Panel considered the information provided on the raw materials as sufficient. The Panel also
considered the information on the manufacturing process as sufficient as long as the filter press is
used. The Panel noted that for the manufacturing processes involving microfiltration, the absence of
the recombinant DNA in de food enzyme cannot be assessed due to absence of data.
3.1.6. Safety for the environment
The production strain and its recombinant DNA were not detected in the final product, when
obtained via the filter press recovery route. Therefore, no environmental risk assessment is required
(EFSA GMO Panel, 2011). Due to the lack of analytical data provided, the Panel is not able to conclude
on the final product if obtained by microfiltration.
3.1.7. Case of need and intended conditions of use
As proposed by the applicant, the food enzyme is intended to be used in baking processes at an
intended use level of up to 15.6 mg TOS/kg flour.
The food enzyme is added to the raw materials during the preparation of dough. It is used to
hydrolyse starch and related polysaccharides, thus contributing to reduce the viscosity of the dough.
The decrease in dough viscosity facilitates the handling of the dough, resulting in more uniform
products with improved crumb resilience and cohesiveness.
3.1.8. Reaction and fate in food
The enzyme maltogenic a-amylase catalyses the hydrolysis of (1?4)-a-D-glucosidic linkages in
polysaccharides like starch and glycogen, thus removing successively maltose residues from the
non-reducing ends of the chains, resulting in the production of maltose and oligosaccharides of
different lengths. These reaction products are naturally present in starch-containing foods. Based on
the substrate specificity of the maltogenic amylase, no unintended reaction products are to be
expected in foods.
According to the data provided on the thermostability, it is anticipated that the maltogenic a-amylase
is inactivated during baking processes under the intended conditions of use.
3.2. Dietary exposure
Exposure estimates were calculated using the methodology described in the CEF Panel statement
on the exposure assessment of food enzymes (EFSA CEF Panel, 2016). The assessment of the food
process, covered in this opinion, involved selection of relevant food groups and application of process
and technical conversion factors (Appendix B). These input data were subjected to a stakeholder
consultation through open calls,6 and adjusted in accordance with feedback received.
3.2.1. EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (hereafter the EFSA
Comprehensive Database7) has been populated with detailed national data on food consumption.
Competent authorities in European countries provide EFSA with data regarding the level of food
consumption by individual consumers, as taken from the most recent national dietary survey in their
country (EFSA, 2011a).
The food consumption data gathered by EFSA were collected using different methodologies and
thus direct country-to-country comparisons should be made with caution. Depending on the food
category and the level of detail used in exposure calculations, uncertainties might be introduced owing
6 http://www.efsa.europa.eu/en/data/call/161110
7 http://www.efsa.europa.eu/en/food-consumption/comprehensive-database
Safety of glucan 1,4-alpha-maltohydrolase from Bacillus subtilis MAM
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2018;16(5):5168
to subjects possibly underreporting and/or misreporting of consumption amounts. Nevertheless, the
EFSA Comprehensive Database is the best available source of food consumption data across Europe.
Food consumption data from the population groups: infants, toddlers, children, adolescents, adults
and the elderly were used for the exposure assessment. For the present assessment, food consumption
data were available from 33 different dietary surveys carried out in 19 European countries (Appendix A).
Consumption records were codified according to the FoodEx classification system (EFSA, 2011b).
3.2.2. Exposure assessment methodology
Chronic exposure was calculated based on individual consumption, averaged over the total survey
period, excluding surveys with only one day per subject. High-level exposure/intake was calculated for
only those population groups, in which the sample size was sufficiently large to allow calculation of the
95th percentile (EFSA, 2011a).
The exposure per FoodEx category (Appendix B) was subsequently added to derive an individual
total exposure per day. Finally, these exposure estimates were averaged over the number of survey
days and normalised for individual body weight (bw), resulting in an individual average exposure/day
per kg bw for the survey period. This was done for all individuals in the survey and per age class,
resulting in distributions of individual average exposure per survey and age class. Based on these
distributions, the mean and 95th percentile exposures were calculated per survey for the total
population and per age class.
3.2.3. Exposure to food enzyme–TOS according to the intended use proposed by
the applicant
Exposure to the food enzyme–TOS was based on intended use and the recommended maximum
use levels of the food enzyme–TOS provided by the applicant (Section 3.1.8). Food enzyme–TOS
exposure was calculated from foods produced involving a baking process.
Relevant food groups and/or individual foods were selected from the Comprehensive Database and
were assumed to always contain the food enzyme–TOS at the maximum recommended use level. This
will result in an overestimation of exposure to food enzyme–TOS.
To facilitate matching of the reported use levels for baking processes with foods identified in the
Comprehensive Database, the selected foods were disaggregated to ingredient level as appropriate,
and converted into the corresponding raw material, i.e. flour, via the application of conversion factors
(Appendix B). For example, consumption of 100 g of bread was converted into an intake of 70 g flour
(recipe fraction of 0.7) and then multiplied by 15.6 mg TOS/kg flour, as provided by the applicant, to
arrive at an exposure of 1.09 mg TOS/100 g bread.
Exposure to the food enzyme–TOS was calculated by multiplying values reported for each food
category by their respective consumption amount per kilogram of body weight (kg bw) separately for
each individual in the database. Table 2 provides an overview of the derived exposure estimates. The
average and 95th percentile exposure to the food enzyme-TOS per age class, country and survey are
reported in Appendix C – Table C.1. The contribution of the food enzyme–TOS from each FoodEx
category to the total dietary exposure is indicated in Appendix C – Table C.2.
Table 2: Summary of estimated dietary exposure to food enzyme–TOS in six population groups
Estimated exposure (mg/kg bw per day)
Population
group Infants Toddlers Children Adolescents Adults The elderly
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3.2.4. Uncertainty analysis
In accordance with the guidance provided in the EFSA Opinion related to uncertainties in dietary
exposure assessment (EFSA, 2007), the following sources of uncertainties have been considered and
are summarised in Table 3.
The conservative approach applied to the exposure estimate to food enzyme–TOS, in particular,
assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led
to a considerable overestimation of the exposure.
3.3. Toxicological data
Table 1 shows that the food enzyme batch 4 used for the toxicological assays has the lowest
specific activity (enzyme activity/mg TOS), which indicates a slightly lower purity than the commercial
batches, and thus can be considered as a ‘worst-case’ scenario. Consequently, on the basis of the data
provided, batch 4 is considered cruder than the three batches for commercialisation and its use for
toxicological testing is considered suitable.
3.3.1. Genotoxicity
3.3.1.1. Bacterial reverse mutation test
To investigate the potential of the maltogenic a-amylase to induce gene mutations in bacteria, a
bacterial reverse mutation assay (Ames test) was performed according to OECD Test Guideline 471
(OECD, 1997a) and following Good Laboratory Practice (GLP). Four strains of Salmonella Typhimurium
(TA1535, TA100, TA1537 and TA98) and Escherichia coli WP2uvrA were used in the presence or
absence of metabolic activation (S9-mix), applying the direct plate incorporation method. Two
experiments were carried out using eight different concentrations of the food enzyme, appropriate
positive control chemicals and sterile deionised water as a negative control. The highest concentration
tested was 5,000 lg/plate, corresponding to 355 lg TOS/plate. All positive controls induced significant
increases in revertant colony numbers, confirming the sensitivity of the tests and the efficacy of the
S9-mix, while the negative controls were within the historical control ranges. Upon treatment with the
food enzyme, there was no increase in revertant colony numbers above control values in any of the
S. Typhimurium strains, with or without metabolic activation.
In E. coli WP2uvrA, a reproducible, dose-related increase in the number of revertants was observed
in the absence of S9-mix, with values above the historical control data range at 3,330 lg/plate,






Consumption data: different methodologies/representativeness/underreporting/
misreporting/no portion size standard
+/–
Use of data from food consumption survey of a few days to estimate long-term
(chronic) exposure for high percentiles (95th percentile)
+
Possible national differences in categorisation and classification of food +/–
Model assumptions and factors
FoodEx categories included in the exposure assessment were assumed to always
contain the food enzyme–TOS
+
Exposure to food enzyme–TOS was always calculated based on the recommended
maximum use level
+
Selection of broad FoodEx categories for the exposure assessment +
Use of recipe fractions in disaggregation FoodEx categories likely to contain the food
enzyme
+/–
Use of technical factors in the exposure model +/–
TOS: total organic solids.
+: uncertainty with potential to cause overestimation of exposure; –: uncertainty with potential to cause underestimation of exposure.
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corresponding to 236 lg TOS/plate. Compared to the solvent control, 1.9- and 2.1-fold increase in the
number of revertants was recorded at this concentration in two experiments.
These results could be due to the concentrations of tryptophan in the test item, exceeding the critical
concentrations used in the plate incorporation assay and thus leading to a false positive outcome. To rule
out this possibility, the applicant was invited to repeat the test applying the ‘treat and plate’ assay.
The applicant did not submit the requested additional data. The Panel considered the data available
as not sufficient to conclude on genotoxicity.
3.3.1.2. In vitro mammalian chromosome aberration test
The in vitro chromosome aberration test was carried out according to the OECD Test Guideline 473
(OECD, 1997b) and following GLP. Duplicate cultures of whole blood were treated with culture medium
(vehicle control), the food enzyme or appropriate positive controls (mitomycin C and
cyclophosphamide, in the absence or presence of S9-mix, respectively). Based on the results of a dose
range finding test, two independent experiments were performed 48 h after mitogen stimulation,
following three treatment schedules: 3 + 21 h in the presence and absence of S9-mix, 24 + 0 and
48 + 0 h without S9-mix. The cultures were exposed to three concentrations of the food enzyme
(1,000, 3,300 and 5,000 lg food enzyme/mL, corresponding to ca. 71, 234 and 355 lg TOS/mL). Two
hundred metaphases per concentration were analysed for chromosomal aberrations. The positive
controls induced statistically significant increases in the frequency of aberrant cells, demonstrating the
sensitivity of the test system and the efficacy of the S9-mix. No cytotoxicity was observed after short
treatment in the presence or absence of S9-mix; in both continuous treatment experiments a dose-
dependent decrease in mitotic index (MI) was observed, up to 56% and 44% of the negative control
at the highest dose (at 24 + 0 and 48 + 0 h, respectively). Frequencies of numerical and structural
chromosomal aberrations were comparable to the negative controls at any dose tested; The
Panel concluded that the food enzyme did not induce chromosomal aberrations under the experimental
conditions applied in this study.
3.3.2. Repeated dose 90-day oral toxicity study in rodents
The repeated dose 90-day oral toxicity study with the food enzyme (batch 4 in Wistar (WU) rats)
was performed in accordance with OECD Test Guideline 408 (OECD, 1998) and following GLP. Doses of
1,394, 4,169 or 13,887 mg food enzyme/kg bw per day, equivalent to 99, 296 or 986 mg TOS/kg bw
per day, at a volume of 13.9 mL/kg bw per day were given to 10 rats/sex by oral gavage. The vehicle
MilliQ-water served as a negative control.
The food enzyme did not have any effect on general health and growth, body weight and food
consumption. No treatment-related changes were observed in haematology, clinical chemistry,
urinalysis, organ weights and organ weight ratios. Gross and histopathology examination did not reveal
any treatment-related changes. In the functional observation tests, a number of endpoints of the
neurological examination showed statistically significant changes (hind limb foot splay, hind limb grip
strength, horizontal counts and time, ambulatory counts and stereotypical time). However, on the basis
of historical control data the Panel concluded that the changes in functional observations were
incidental.
Overall, the Panel derived a no observed adverse effect level (NOAEL) at the high dose level of
986 mg TOS/kg bw per day for both males and females.
A comparison of the NOAEL (986 mg TOS/kg bw per day) from the 90-day study with the derived
exposure estimates in six human population groups of 0.004–0.098 mg TOS/kg bw per day at the
mean and from 0.033 to 0.175 mg TOS/kg bw per day at the 95th percentile, resulted in a margin of
exposure (MOE) of 5,634, indicating that there is no concern.
3.4. Allergenicity
The allergenicity assessment considers only the food enzyme and not any carrier or other excipient
which may be used in the final formulation.
The allergenicity of glucan 1,4-a-maltohydrolase produced with the genetically modified
B. subtilis strain MAM was assessed by comparing its amino acid sequence with those of known allergens
according to the EFSA Scientific opinion on the assessment of allergenicity of GM plants and
microorganisms and derived food and feed of the Scientific Panel on Genetically Modified
Organisms (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino
acids as criterion, one match was found with Asp o 21, an a-amylase from A. oryzae.
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a-amylase from A. oryzae is described as an occupational respiratory allergen associated with baker’s
asthma (Brisman and Belin, 1991; Brisman, 2002). However, several studies have shown that adults with
occupational asthma to a food enzyme (like a-amylase) can commonly ingest the corresponding enzyme
without acquiring clinical symptoms of food allergy (Cullinan et al., 1997; Brisman, 2002; Poulsen, 2004;
Armentia et al., 2009). Taking into account the wide use of a-amylase as a food additive, only a low
number of case reports have been described in literature focusing on allergic reactions upon oral
exposure to a-amylase in individuals’ respiratory sensitised to a-amylase (Baur and Czuppon, 1995;
Kanny and Moneret-Vautrin, 1995; Moreno-Ancillo et al., 2004). Therefore, it can be concluded that the
likelihood of an allergic reaction upon oral ingestion of glucan 1,4-a-maltohydrolase, produced with the
genetically modified strain of B. subtilis strain MAM, in individuals respiratory sensitised to a-amylase
cannot be excluded, but the likelihood is considered to be low. In addition, no information is available on
oral sensitisation or elicitation reactions of this glucan 1,4-a-maltohydrolase.
The potential cross-reactivity of food enzymes was studied by Bindslev-Jensen et al. (2006) There
were no indications of cross reactivity between 19 different commercial food enzymes and the main
allergens represented by 400 patients (allergic to inhalation allergens, food allergens, allergens of bee
or wasp or drugs) included in this study.
Taken together, the Panel considers that there are no indications for allergic reactions by dietary
exposure to the food enzyme glucan 1,4-a-maltohydrolase produced with the genetically modified
B. subtilis strain MAM.
Conclusions
No safety concerns were identified in relation to the genetic modifications, the manufacturing
process, the compositional data, the dietary exposure, as well as the allergenicity assessment.
Regarding the toxicological studies, the repeated dose 90-day oral toxicity study also did not raise a
safety concern. However, owing to the incompleteness of the genotoxicity data, the Panel is not able
to conclude on the safety of the food enzyme glucan 1,4-a-maltohydrolase produced with B. subtilis
strain MAM by the company DSM Food Specialties B. V. In addition, the Panel emphasises that the
assessment covers only the food enzyme recovered via filter press.
The Panel noted that data are lacking to conclude on compliance of the food enzyme with the
requirements of Regulation 1333/20088
Documentation provided to EFSA
1) Dossier ‘Glucan 1,4-alpha-maltohydrolase from a genetically modified strain of Bacillus subtilis
(MAM)’, October 2013. Submitted by DSM Food Specialties B.V.
2) Additional information was received from DSM in June 2014.
3) Additional information was received from DSM in August 2014.
4) Additional information was received from DSM in August 2015.
5) Additional information was received from DSM in May 2017.
6) Additional information was received from DSM in October 2017.
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Abbreviations
Bw body weight
CAS Chemical Abstracts Service
CEF EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids
CFU colony Forming Units
CHO Chinese Hamster Ovary
FAO Food and Agricultural Organization
FSSC Food Safety Systems Certification
GLP Good Laboratory Practice
GM genetically modified
GMO genetically modified organisms
GMP Good Manufacturing Practice
IUBMB International Union of Biochemistry and Molecular Biology
MOE Margin of exposure
NADH nicotinamide adenine dinucleotide-hydrogen (reduced)
NMAU New Maltogenic Amylase Units
NOAEL no observed adverse effect level
OECD Organisation for Economic Cooperation and Development
PCR polymerase chain reaction
QPS Qualified Presumption of Safety
rRNA ribosomal ribonucleic acid
SDS-PAGE sodium dodecyl sulfate-poly acrylamide gel electrophoresis
TOS Total Organic Solids
WHO World Health Organization
WU Wistar
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Appendix A – Population groups considered for the exposure assessment
Population Age range
Countries with food consumption surveys covering more
than one day
Infants From 12 weeks on up to and
including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, United Kingdom
Toddlers From 12 months up to and
including 35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany, Italy, Netherlands,
Spain, United Kingdom
Children(a) From 36 months up to and
including 9 years of age
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland,
France, Germany, Greece, Italy, Latvia, Netherlands, Spain, Sweden,
United Kingdom
Adolescents From 10 years up to and
including 17 years of age
Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland,
France, Germany, Italy, Latvia, Spain, Sweden, United Kingdom
Adults From 18 years up to and
including 64 years of age
Austria, Belgium, Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Romania,
Spain, Sweden, United Kingdom
The elderly(a) From 65 years of age and
older
Austria, Belgium, Denmark, Finland, France, Germany, Hungary,
Ireland, Italy, Romania, Sweden, United Kingdom
(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a).
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Appendix B – FoodEx categories used to derive exposure estimates for the
food enzyme–TOS and the respective conversion factors









A.01 Grains and grain-based products
(unspecified)
0.8 1 15.6
A.01.03 Grain milling products (unspecified) 1 1 15.6
A.01.03.001 Wheat milling products (unspecified) 1 1 15.6
A.01.03.001.001 Wheat flour, brown 1 1 15.6
A.01.03.001.002 Wheat flour, Durum 1 1 15.6
A.01.03.001.003 Wheat flour, white 1 1 15.6
A.01.03.001.004 Wheat flour, wholemeal 1 1 15.6
A.01.03.001.005 Graham flour 1 1 15.6
A.01.03.001.006 Wheat flour, gluten free 1 1 15.6
A.01.03.001.014 Wheat starch 1.2 1 15.6
A.01.03.002 Rye milling products (unspecified) 1 1 15.6
A.01.03.002.001 Rye flour, gluten free 1 1 15.6
A.01.03.002.002 Rye flour, light 1 1 15.6
A.01.03.002.003 Rye flour, medium 1 1 15.6
A.01.03.002.004 Rye flour, wholemeal 1 1 15.6
A.01.03.003 Buckwheat milling products (unspecified) 1 1 15.6
A.01.03.003.001 Buckwheat flour 1 1 15.6
A.01.03.004 Corn milling products (unspecified) 1 1 15.6
A.01.03.004.001 Corn flour 1 1 15.6
A.01.03.004.003 Corn starch 1.3 1 15.6
A.01.03.005 Oat milling products (unspecified) 1 1 15.6
A.01.03.005.002 Oat flour 1 1 15.6
A.01.03.005.004 Oat starch 1.2 1 15.6
A.01.03.006 Rice milling products (unspecified) 1 1 15.6
A.01.03.006.001 Rice flour 1 1 15.6
A.01.03.006.002 Rice flour white 1 1 15.6
A.01.03.006.003 Rice flour, instant 1 1 15.6
A.01.03.006.004 Rice starch 1.2 1 15.6
A.01.03.007 Spelt milling products 1 1 15.6
A.01.03.008 Other milling products (unspecified) 1 1 15.6
A.01.03.008.001 Amaranth flour 1 1 15.6
A.01.03.008.002 Barley flour 1 1 15.6
A.01.03.008.003 Chapatti flour 1 1 15.6
A.01.03.008.004 Flour mix, wheat/rye/barley/oats 1 1 15.6
A.01.03.008.005 Millet flour 1 1 15.6
A.01.03.008.007 Sorghum flour 1 1 15.6
A.01.04 Bread and rolls (unspecified) 1 0.7 15.6
A.01.04.001 Wheat bread and rolls 1 0.7 15.6
A.01.04.002 Rye bread and rolls 1 0.7 15.6
A.01.04.003 Mixed wheat and rye bread and rolls 1 0.7 15.6
A.01.04.004 Multigrain bread and rolls 1 0.7 15.6
A.01.04.005 Unleavened bread, crisp bread and rusk
(unspecified)
1 0.8 15.6
A.01.04.005.001 Crisp bread, rye wholemeal 1 0.9 15.6
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A.01.04.005.002 Crisp bread, rye, light 1 0.9 15.6
A.01.04.005.003 Crisp bread, wheat, wholemeal 1 0.9 15.6
A.01.04.005.004 Crisp bread, wheat, light 1 0.9 15.6
A.01.04.005.005 Rusk, light 1 0.9 15.6
A.01.04.005.006 Rusk, wholemeal 1 0.9 15.6
A.01.04.005.007 Pita bread 1 0.7 15.6
A.01.04.005.008 Matzo 1 0.9 15.6
A.01.04.005.009 Tortilla 1 0.7 15.6
A.01.04.006 Other bread 1 0.7 15.6
A.01.04.007 Bread products 1 0.7 15.6
A.01.07 Fine bakery wares (unspecified) 1 0.5 15.6
A.01.07.001 Pastries and cakes (unspecified) 1 0.5 15.6
A.01.07.001.001 Beignets 1 0.15 15.6
A.01.07.001.002 Buns 1 0.7 15.6
A.01.07.001.003 Cake from batter 1 0.25 15.6
A.01.07.001.004 Cheese cream cake 1 0.24 15.6
A.01.07.001.005 Cheese cream sponge cake 1 0.24 15.6
A.01.07.001.006 Chocolate cake 1 0.24 15.6
A.01.07.001.007 Chocolate cake with fruits 1 0.24 15.6
A.01.07.001.008 Cream cake 1 0.24 15.6
A.01.07.001.009 Cream cheese cake 1 0.24 15.6
A.01.07.001.010 Cream custard cake 1 0.24 15.6
A.01.07.001.011 Cream custard sponge cake 1 0.24 15.6
A.01.07.001.012 Croissant 1 0.5 15.6
A.01.07.001.013 Croissant, filled with chocolate 1 0.5 15.6
A.01.07.001.014 Croissant, filled with cream 1 0.5 15.6
A.01.07.001.015 Croissant, filled with jam 1 0.5 15.6
A.01.07.001.016 Croquembouche 1 0.15 15.6
A.01.07.001.017 Doughnuts 1 0.24 15.6
A.01.07.001.018 Clair 1 0.15 15.6
A.01.07.001.019 Flan 1 0.5 15.6
A.01.07.001.020 Fruit cake 1 0.6 15.6
A.01.07.001.021 Fruit pie 1 0.15 15.6
A.01.07.001.022 Cheese pie 1 0.15 15.6
A.01.07.001.023 Fruit tart 1 0.15 15.6
A.01.07.001.024 Gingerbread 1 0.6 15.6
A.01.07.001.025 Gougere 1 0.15 15.6
A.01.07.001.026 Kringles 1 0.25 15.6
A.01.07.001.027 Nut cream cake 1 0.24 15.6
A.01.07.001.028 Pancakes 1 0.25 15.6
A.01.07.001.029 Profiterole 1 0.15 15.6
A.01.07.001.030 Pyramid cake 1 0.25 15.6
A.01.07.001.031 Rhubarb flan 1 0.15 15.6
A.01.07.001.032 Scone 1 0.5 15.6
A.01.07.001.033 Sponge dough 1 0.25 15.6
A.01.07.001.034 Sponge cake 1 0.25 15.6
A.01.07.001.035 Sponge cake roll 1 0.25 15.6
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A.01.07.001.036 Muffins 1 0.25 15.6
A.01.07.001.037 Waffles 1 0.25 15.6
A.01.07.001.038 Apple strudel 1 0.15 15.6
A.01.07.001.039 Cream-cheese strudel 1 0.24 15.6
A.01.07.001.040 Cheese pastry goods from puff pastry 1 0.15 15.6
A.01.07.001.041 Croissant from puff pastry 1 0.6 15.6
A.01.07.001.042 Brioche 1 0.5 15.6
A.01.07.001.044 Lebkuchen 1 0.6 15.6
A.01.07.001.045 Dumpling 1 0.5 15.6
A.01.07.001.046 Cake marbled, with chocolate 1 0.5 15.6
A.01.07.001.047 Marzipan pie 1 0.25 15.6
A.01.07.001.048 Baklava 1 0.15 15.6
A.01.07.002 Biscuits (cookies) 1 0.9 15.6
A.01.07.002.001 Biscuits, sweet, plain 1 0.9 15.6
A.01.07.002.002 Biscuits, chocolate filling 1 0.81 15.6
A.01.07.002.003 Biscuits, cream filling 1 0.81 15.6
A.01.07.002.004 Biscuits, fruit filling 1 0.81 15.6
A.01.07.002.005 Biscuits, vanilla filling 1 0.81 15.6
A.01.07.002.006 Butter biscuits 1 0.81 15.6
A.01.07.002.007 Biscuit, iced 1 0.81 15.6
A.01.07.002.008 Speculaas 1 0.9 15.6
A.01.07.002.009 Biscuits, sweet, wheat wholemeal 1 0.9 15.6
A.01.07.002.010 Biscuits, oat meal 1 0.9 15.6
A.01.07.002.011 Biscuits, spelt meal 1 0.9 15.6
A.01.07.002.012 Biscuits, salty 1 0.9 15.6
A.01.07.002.013 Biscuits, salty, with cheese 1 0.81 15.6
A.01.07.002.014 Sticks, salty 1 0.81 15.6
A.17.03.003 Biscuits, rusks and cookies for children 1 0.9 15.6
A.18.04.001 Find bakery products for diabetics 1 0.5 15.6
A.19.01.001 Sandwich and sandwich-like meal 1 0.32 15.6
A.19.01.002 Pizza and pizza-like pies 1 0.3 15.6
TOS: total organic solids.
(a): Available at see http://www.fao.org/fileadmin/templates/ess/documents/methodology/tcf.pdf
(b): Derived from publically available recipe information, and/or food label information (such as Mintel’s Global New Products
Database http://www.mintel.com/global-new-products-database).
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Appendix C – Dietary exposure estimates to the food enzyme–TOS in
details
Information provided in this appendix is shown in an excel file (downloadable http://onlinelibrary.
wiley.com/wol1/doi/10.2903/j.efsa.2018.5168/suppinfo).
The file contains two sheets, corresponding to two tables.
Table C.1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country
and survey.
Table C.2: The contribution of the food enzyme–TOS from each FoodEx category to the total dietary
exposure.
Safety of glucan 1,4-alpha-maltohydrolase from Bacillus subtilis MAM
www.efsa.europa.eu/efsajournal 20 EFSA Journal 2018;16(5):5168
